Show simple item record

dc.contributor.authorSmith, HG
dc.contributor.authorJamal, K
dc.contributor.authorDayal, JH
dc.contributor.authorTenev, T
dc.contributor.authorKyula-Currie, J
dc.contributor.authorGuppy, N
dc.contributor.authorGazinska, P
dc.contributor.authorRoulstone, V
dc.contributor.authorLiccardi, G
dc.contributor.authorDavies, E
dc.contributor.authorRoxanis, I
dc.contributor.authorMelcher, AA
dc.contributor.authorHayes, AJ
dc.contributor.authorInman, GJ
dc.contributor.authorHarrington, KJ
dc.contributor.authorMeier, P
dc.date.accessioned2020-05-21T12:07:39Z
dc.date.issued2020-06
dc.identifier.citationEMBO molecular medicine, 2020, 12 (6), pp. e10979 - ?
dc.identifier.issn1757-4676
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3622
dc.identifier.eissn1757-4684
dc.identifier.doi10.15252/emmm.201910979
dc.description.abstractDrugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti-tumour immunity but not every form of death can elicit an immune response. Moreover, resistance to apoptosis is a major problem in cancer treatment and disease control. While the term "immunogenic cell death" is not fully defined, activation of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) can induce a type of death that mobilises the immune system against cancer. However, no clinical treatment protocols have yet been established that would harness the immunogenic potential of RIPK1. Here, we report the first pre-clinical application of an in vivo treatment protocol for soft-tissue sarcoma that directly engages RIPK1-mediated immunogenic cell death. We find that RIPK1-mediated cell death significantly improves local disease control, increases activation of CD8 + T cells as well as NK cells, and enhances the survival benefit of immune checkpoint blockade. Our findings warrant a clinical trial to assess the survival benefit of RIPK1-induced cell death in patients with advanced disease at limb extremities.
dc.formatPrint-Electronic
dc.format.extente10979 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleRIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.
dc.typeJournal Article
dcterms.dateAccepted2020-04-20
rioxxterms.versionofrecord10.15252/emmm.201910979
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEMBO molecular medicine
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL)
pubs.publication-statusPublished
pubs.volume12
pubs.embargo.termsNot known
icr.researchteamCell Death and Immunityen_US
icr.researchteamSarcoma and Melanoma Surgeryen_US
icr.researchteamTranslational Immunotherapyen_US
dc.contributor.icrauthorMeier, Pascalen
dc.contributor.icrauthorJamal, Kunzahen
dc.contributor.icrauthorHayes, Andrewen
dc.contributor.icrauthorMelcher, Alanen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0